Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.23 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.46 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.92 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene australia pty ltd - lenalidomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene australia pty ltd - azacitidine -

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - romidepsin, quantity: 10 mg - injection, powder for - excipient ingredients: povidone; dilute hydrochloric acid - istodax is indicated for the treatment of peripheral t-cell lymphoma in patients who have received at least one prior systemic therapy.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - thalidomide - multiple myeloma - immunosuppressants - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy.thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.4).

European Union - English - EMA (European Medicines Agency)

celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antithrombotic agents - anticoagulation in adult patients with heparin-induced thrombocytopenia type ii and thromboembolic disease mandating parenteral antithrombotic therapy.the diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - lenalidomide, quantity: 20 mg - capsule, hard - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm) revlimid is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) revlimid is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) revlimid is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - lenalidomide, quantity: 7.5 mg - capsule, hard - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm) revlimid is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) revlimid is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) revlimid is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.